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ABSTRACT  
TITLE  
“CLINICOPATHOLOGICAL ANALYSIS ON EPITHELIAL OVARIAN 
CARCINOMA”  
AIM AND OBJECTIVE  
1. To analyse various factors associated with epithelial ovarian carcinoma  
2. To study the various clinical presentation, ideal  investigations and 
management and its impact on outcome of epithelial ovarian carcinoma  
SETTING  
Medical oncology Department  
Institute of obstetrics and Gynaecology, Egmore Chennai – 600 008. 
STUDY DESIGN  
Analytical Study  
PERIOD :  One and half years  
ETHICAL CLEARANCE   
Ethical clearance   obtained  
SAMPLE  
Patients Diagnosed and treated for epithelial ovarian carcinoma at IOG for a period of 
one and a half years (June 2012 – Dec 2013)  
Materials And Methods  
An analysis  of patients who underwent therapy for epithelial ovarian carcinoma at 
IOG Egmore from June 2012 to Dec 2013 were conducted. Patients were examined 
for demographic details, presenting signs and symptoms, diagnostic modalities   
complications, Data was analyzed. Test of significance – Pearson Chi square test. 
 
   89 patients  diagnosed as epithelial ovarian carcinoma were included in the study. 
Demographic details were collected. Detailed history and examination was done.  
Serum CA 125 was done. Histopathology ( surgery or ascitic fluid analysis) report 
2obtained.  Type of  surgery  and  chemotherapy given was  analysed. 
Maximum number of patients were between age group 41 and 50 years.    
Mean age of presentation  was at 50 years. Most of the women presented with 
complaints of distension and pain abdomen and gastrointestinal symptoms. Serum  
CA 125 level was raised in most of cases of epithelial  ovarian cancer other than 
mucinous.   CA 125 level  was normal in most of the early stage  carcinoma. 
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INTRODUCTION
1INRODUCTION
Ovarian cancer has become increasingly important because they
have gradually increased the mortality rate due to female genital cancer.
Ovarian cancer is the leading cause of death  due to gynecological
malignancies among women in the world. Ovarian cancer is the second
most  common  of  all  genital  cancers  and  accounts   for  10-15%  of  all
gynecological cancers in India. Epithelial ovarian cancers account for
about 90% of ovarian malignancies.
The risk of woman developing cancer of the ovary in her lifetime is
1- 1.5% and that of dying from ovarian cancer is 0.5%. Risk factors for
ovarian carcinoma include nulliparity, early menarche, late menopause,
infertility, age, asbestosis talc personal history of breast or  endometrial
cancer and family history of breast or endometrial cancer.
The objective of this study is to evaluate the clinicopathologic
characteristics, treatment strategies and and its impact on prognosis of
epithelial ovarian carcinoma. A  review of the patients who were registered
from June 2012 to December   in Medical Oncology Department  IOG
Egmore   and   underwent  therapy  for  epithelial  ovarian  carcinoma   were
conducted. Patients were examined for presenting  signs and symptoms,
2diagnostic modalities ,laboratory values surgical procedures ,pathological
features and post operative complications.
Data was  entered in to a standard proforma and analyzed.  Most of
the patients were from Chennai and places  around Chennai. Few patients
were from places other than chennai from various places of Tamil Nadu.
There were few patients from nearby states. This study presents the single
institute experience regarding the clinicopathologic characteristics and
treatment strategies in epithelial ovarian carcinoma.
AIM OF THE STUDY
3AIM   OF THE  STUDY
To  analyse   various  factors  associated  with  epithelial  ovarian
carcinoma To study  the  various clinical  presentation,  ideal investigations
and  management  and  its   impact   on  outcome  of  epithelial  ovarian
carcinoma .
REVIEW OF LITERATURE
4REVIEW OF LITERATURE
Ovarian cancer accounts  for  30 %  malignancies  of  the  female  genital
tract in the developed countries. The incidence ovarian cancer increases
with age and it peaks in  the  eighth decade. About 40 %  epithelial ovarian
cancer  occurs  at more than  70 years of age. The median age at diagnosis
is  63 years. Epithelial ovarian cancer is a disease  of older age.
Childbearing and breast feeding protect against the development of
ovarian cancer. Protection offered  by the  contraceptive pills  is thought to
be due to the reduction  in number of ovulation. Reduction in number of
ovulation minimizes the damage and repair of surface epithelium. In the
past few decades, there is reduction in parity and it may be a reason for
increased incidence  of ovarian cancer.
Most of the cases of epithelial ovarian carcinoma are sporadic.  Only a
small percentage of epithelial ovarian carcinoma are familial.
5RISK FACTORS
The risk factors associated with ovarian cancer are
? Older age groups
? Nulliparity
? Infertility
? Early menarche
? Late menopause
? White race
? Endometriosis
? Pelvic inflammatory disease
? Family h/o cancers Ovary, breast Endometrium, colon
? Diet rich in animal fat
? Perinal exposure to talc
6Incessant ovulation is thought to be an important aetiological factor.
This explains the increased risk in nulliparous women, women with early
menarche and late menopause and women with infertility.
Prolonged use of ovulation induction drugs like clomiphene citrate
has also been implicated. Maximun number of clomiphene induced  Cycles
allowed is 12. But it is ideal to stop its use after six cycles.
FAMILY HISTORY
Whereas women with no family history of ovarian cancer have a 1.5
% lifetime risk of developing the disease, those with one affected first
degree relative have a 5 % risk and women with two first degree relatives
have  a  7  %  risk.  5  to  10  %  of  cases  of  ovarian  cancer  are  thought  to  be
familial. Inherited mutations in BRCA 1 and BRCA 2 genes predispose to
both breast and ovarian cancer.  It is Mendelian dominant and  have 80 %
penetrance. BRCA 1 is a large gene with 1,00,000 base pairs, any one of
which may be mutated.
It is found in 5 % of women diagnosed with ovarian cancer before
the age of 70 years. Estimates of the lifetime risk ofcancer associates with
BRCA mutations are variable and depend upon the population studied. It
7ranges  from15  to60  %  to  ovarian  cancer  when  compared  with   1.5  %
lifetime risk  among the general population. There are several other genes
that predisposes to ovarian cancer. HNPCC is Hereditory Non Polyposis
Colorectal cancer  also called as Lynch II cancer. Some of these oncogenic
genes associated with ovarian cancer are associated with HNPCC. HNPCC
carrier  have 9-12 % lifetime risk of ovarian cancer.
Hereditory ovarian  cancers  occur about 10 years earlier  than the
sporadic  ovarian cancers at the mean age of 50 years.  The risk of carrying
a gene for ovarian cancer increases with number of relatives with the same
cancer.  When two first degree relatives are affected, the possibility of
carrying an affected gene is 35 t0 40 %.
The genetic predisposition for an individual woman can be difficult
to determine without expert knowledge. Multiple primary cancers in one
individual or related early  onset cancer s in a family tree are suggestive of
a predisposing gene. Except for those families where a specific gene
abnormality is  identifiable, there are few families  in which it is possible
To be sure of  dominant inheritance. When there are four first degree
relatives with early onset or bilateral breast cancer in combination with
ovarian cancer  the risk of inheriting  a mutated gene is nearly 50 %.
8APPROXIMATE LIFETIME PERCENTAGE RISK OF
DEVELOPING OVARIAN CANCER
POPULATION                                                               LIFETIME RISK
1. General population 1.5%
2. One first degree relative affected 5.2%
under 55 years
3. One first degree relative affected 3.4%
Over 55 years
4. Two first degree relatives affected 7 %
5. BRCA 1 carrier 28- 44 %
6. BRCA 2 carrier 27%
7. HNPCC carrier 12 %
Careful family history should be taken and referral to the clinical
cancer genetics should be done. Those women who are assessed to be of
9increased risk should be offered annual transvaginal ovarian  ultrasound
and serum CA 125 tumour marker blood test. Screening  should start at the
age of 30 years or 5 years before the age of onset  of the first ovrian cancer
in the family.  Testing for gene mutations  is  very costly, it costs around
60,000  to 1,00,000 Rs for   testing BRCA 1 gene.
 Specific gene mutation is the family is known, that gene can be
tested  in  the   women  of  that  family.  Hence    prophylactic   risk  reducing
surgery is recommended for BRCA1 and BRCA2 carries, once  family  is
completed  as they have high percentage risk of developing ovarian cancer.
Kauff  ND et al studied the risk reducing salpingo oophorectomy in
women with mutation in  BRCA 1 or BRCA 2 . It was a prospective study
of 170  women . They claim a risk reduction from 6.9% to 3.1 % .  This is
after a mean period of 2 years.
Surgery  consists  of  bilateral  salpingo-  oophorectomy.  It   may  be
through laparotomy or laparoscopic as per expertise. It is usually
laparoscopic salpingo-oophorectomy. HNPCC carriers are also offered
hysterectomy.  Neither prophylactic  salpingo oophorectomy nor screening
completely eliminate the risk of developing ovarian cancer.
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          Screening  is not proven to improve survival. Even if the ovaries are
removed  there is a small continuing risk of developing primary peritoneal
cancer. The United Kingdom Familial Ovarian Cancer Screening Study
(UKFOCSS)   recruited 3,563 high risk women.
The  high  risk  was   either due to family history or BRCA 1 or 2
gene mutation.  In part 1 of the trial woman had annual TVS and CA 125.
It has been found that annual screening lacked sensitivity for early stage
disease. It  has  been  found  that  it  down staged disease volume and  that
it  may have  improved optimal debulking rate
CRITERIA FOR CATEGORISATION  OF A WOMAN AS AT
HIGH RISK  OF OVARIAN CANCER
1. Two or more first degree relatives affected by ovarian cancer
2. One first degree relative with ovarian cancer and one with breast
cancer diagnosed before the age of 50 years. One first degree
relative with ovarian cancer and two with breast cancer diagnosed
before the age of 60 years.
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3. An individual with a mutation of one of the genes known to
predispose to ovarian cancer.
4. Three first degree relatives with colorectal cancer with atleast one
diagnosed below the age of 50 years, as well as one  case of  ovarian
cancer.
Borderline ovarian tumous rarely precede invasive carcinoma.
Hence identification of a   premalignant stage in ovarian cancer has yet to
be identified. The multicentric United Kingdom Collaborative Trial of
Ovarian Cancer Screening (UKCTOCS) is the largest study of its kind to
date, results are awaited
Whether the screening has an effect on the mortality will be known
when the trial is concluded in 2014. The study also aims to address the
cost, acceptance, physical and psychological morbidity. Currently there is
no indication  to screen for ovarian carcinoma in low risk women  i.e.,
without a familial history of ovarian and breast cancer.
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SCREENING METHODS
 Since effective screening method is not  available  and  early stage
disease  is silent most ovarian cancer are diagnosed at an advanced stage.
Methods used for screening are
? Routine yearly pelvic examination
? Tumour markers-
o CA 125,
o CA-19-9. CA 15-3
o Lipid associated sialic acid
o Osteopontin
? Transvaginal ultrasound
? Proteomic patterns
o Genetic testing- in indicated patients.
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o Of the screening methods annual pelvic examination has  a
low sensitivity for  diagnosing   ovarian cancer.
CA125
CA 125  is a   tumour  marker of epithelial ovarian malignancy. CA
125 stands for Cancer Antigen 125. It was named so because it was the
125th antibody when testing  for various antibody against ovarian tumour
was performed. It is tested by drawing venous sample of  blood.  Normal
level of   CA 125 is 0 – 35 U/mL. A cut off value of 35 U/mL is used in
postmenopausal women. In premnopausal women a cut off of 200 U/mL
is recommended. Bast  and  collegues  described  first about  CA 125  in
1983.
CA 125  is produced in small quantities by by normal   ovarian
epithelial cells. It is also produced by peritoneal lining cells, lining cells of
Gastro Intestinal Tract, pancreas breast and lung.
It is non specific in that it is raised in non cancerous conditions like
normal menstruation, pregnancy, endometriosis, fibroids, pelvic
inflammatory disease, ovarian cysts, liver diseases such as cirrhosis or
hepatitis, pancreatitis and other cancers like pancreatic and lung cancer.
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The test is used along with transvaginal ultrasound  in multimodal
screening.
Serial estimation of CA 125 has been found to be more  useful than
a  single value for screening. When used alone, CA 125  lacks specificity
and the sensitivity is about 50%.  It is being used  in  ovarian cancer
screening  in high risk woman and in calculating RMI.
NICE suggests  CA 125 for women with symptoms of  bloating,
feeling full quickly, loss of appetite, pelvic or abdominal pain and
frequent  or urgent micturition.  CA 125 levels are processed using
ROCA,  risk  of  Ovarian  Cancer  Algorithm,  which   stratifies  women
according to age, post menopausal status and pattern of CA 125 over time .
In UKFOCSS, United Kingdom Familial Ovarian Cancer  Screening
Study,  phase  2  annual  TVS and  four  monthly  CA 125  are  done.   Results
are awaited.
TRANSVAGINAL ULTRASONOGRAPHY
TVS is used to differentiate  between benign and malignant tumours
of the ovary. Ultrasonographic characteristics of malignancy are
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? Ovarian volume > 10 cm3
? Solid / complex ( solid and cystic)
? Multiloculated
? Thickness of cyst wall (> 3 mm)
? Septal thickness ( > 2 mm )
? Bilateral
? Papillary excresences
? Increase in vascularity
? Doppler resistance index  < 0.40
Due to neovascularisation of  malignant  tissue,   the   blood flow  is
increased  and  resistance  is  low. This  can  be  measured  using   Doppler
and  resistance  index  calculated.  Ultrasonography  has  a  high
sensitivity.   But  it  has  low  specificity   for   diagnosis   of  early    ovarian
cancer.
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PROTEOMIC PATTERNS
Proteomic   patterns   are   proteins   and   protein   fragments   that
circulate  in  the  blood.  They  indicate  early  changes  caused  by  genetic
mutations.
PREVENTION
In women  who are at high risk   for  ovarian  cancer,  prophylaxix is
indicated.  The  methods  used  are
? Oral contraceptives
? Prophylactic bilateral salpingo oopherectomy
? Tubal sterilization
? Hysterectomy
Chemoprevention with oral contraceptives is a proven method of
prevention.  The protective effect persists for 10 years or more  after
stopping  the  medication.  Prophylactic  salpingo  oophorectomy  is
recommended   at   an   age   more   than   35   years   after   these   women
complete  their  family.  This  procedure  reduces  the  risk  by  90 %.
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PRESENTING FEATURES
Ovarian cancer is often described as a silent killer. But early
symptoms are frequently noted.  Abdominal bloating is frequent
presentation. Urinary frequency, a sense of  fullness  and  abdominal  and
pelvic pain are the other symptoms.
The symptoms are often dismissed  byhealth care professionals as
these are nonspecific. Hence the ovarian cancer is usually diagnosed  at an
advanced stage when the prognosis is poor. NICE suggests  CA 125 for
women with  these symptoms  suggestive of epithelial ovarian malignancy
WHO  CLASSIFICATION  OF  OVARIAN  TUMOURS
1.  EPITHELIAL TUMOURS
2.  GERM  CELL  TUMOURS
3. LIPID ( LIPOID ) CELL TUMOUR
4. SEX CORD ( STROMAL ) TUMOURS
5. GONADOBLASTOMAS
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6. SOFT TISSUE TUMOURS NOT SPECIFIC TO OVARY
7. UNCLASSIFIED TUMOURS
8. SECONDARY ( METASTATIC) TUMOURS
9. TUMOUR LIKE CONDITIONS
The  majority   of   ovarian   tumours  are  epithelial.   59  %  of  all
ovarian  tumours  and  up to  90 %    of   all   the ovarian  malignancies  are
epithelial.  These  arise   from   the   cells   covering   the   surface   of    the
ovary and  probably  also  from  the  fimbrial  end  of  the  fallopian  tube.
Less frequently  they  arise  from  the  endometriotic   implants  within  the
ovaries.   Pathological   classification  is   made  according  to  the  WHO
classification.
Epithelial  tumours  can  be  further  classified  as:
? SEROUS EPITHELIAL CARCINOMA
? MUCINOUS EPITHELIAL CARCINOMA
? ENDOMETROID EPITHELIAL CARCINOMA
? CLEAR CELL EPITHELIAL CARCINOMA
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? TRANSITIONAL OR BRENNAR EPITHELIAL
CARCINOMA
? UNCLASSIFIABLE EPITHELIAL CARCINOMA
? MIXED EPITHELIAL CARCINOMA
? UNDIFFERENTIATED EPITHELIAL CARCINOMA
Serous  tumours  are  the  most  common  subtype  and  account  for
about  50  %
Next  frequent  is endometroid epithelial carcinoma
           Pseudomyxoma peritonei results from rupture of mucinous tumour
           Clear cell tumours are rare
            Brennar tumour is called  transitional tumour
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CUT SECTION  PAPILLARY SEROUS CYSTADENO
CARCINOMA
? Papillary  growth
21
HPE PAPILLARY SEROUS CYSTADENO CARCINOMA
? Keratinisation
22
HPE PAPILLARY SEROUS CYSTADENO CARCINOMA
? Increased nuclear cytoplasm ratio.
? Tall columnar cells resembling endosalpinx
23
MUCINOUS CYSTADENO CARCINOMA
24
PHOTO MICROGRAPH  OF  MUCINOUS  CYSTADENO
CARCINOMA
? Columnar mucin secreting epithelium
25
EXTERNAL SURFACE OF MALIGNANT EPITHELIAL
ENDOMETROID ADENOCARCINOMA
CUT SECTION
26
PHOTOMICROGRAPH OF ENDOMETRIOID ADENO
CARCINOMA
? Increased nuclear cytoplasm ratio.
? Glandular epithelium resembling endometrium.
27
PHOTOMICROGRAPH OF CLEAR CELL  CARCINOMA
.
? Increased nuclear cytoplasm ratio.
? Large cuboidal epithelial cells
? Hob nail pattern.
28
GRADE
Malignant  tumours  are  graded as I, II, III  i.e  well, moderately,
poorly differentiated  according to pattern  of  growth  and  cytology.
PRIMARY PERITONEAL TUMOUR
Peritoneum  can  undergo  malignant  transformation  into  primary
peritoneal  carcinoma.  When disseminated metastatic epithelial ovarian
cancer like picture is seen  with  normal  looking  ovaries primary
peritoneal  carcinoma is diagnosed.  can  be  indistinguishable clinically
and  histologically   from  metastatic  epithelial  ovarian  cancer.
BORDERLINE  TUMOURS
            Borderline  ovarian     tumours      are     from   the   ovarian
epithelium.  They  are  of   a   category   from  clearly   benign   and   clearly
malignant  .   The    behavior  of  these   tumours   is   more   indolent.   They
may   be   associated   with   extra  ovarian   disease   of   similar   histology
with  the presence of  implants  in  omentum and  peritoneum.
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 Thus  it   may  be  possible  to  have  advanced  stage  borderline
disease.   Other   terms  used  to   describe  the  borderline  tumours  are
carcinoma  of   low   malignant   potential   and   atypical   proliferating
tumour.  The  term  borderline  tumour  is  accepted  by  the WHO.
Bordeline tumours are typically  found in  a younger  population
than  frank  epithelial   cancers.  One  third occur  in  women  under   40
years.  Overall Prognosis will be  good.  Recurrences  have  been  reported
as   late   as   30   years  after   initial   presentation.  A   women   after   a
unilateral  salpingo oopherectomy  and diagnosed as borderline tumour
have to be informed   that  there is 7 %  recurrence  risk  without  further
surgery.
Benefit of chemotherapy  in borderline  tumours  lacks evidence.  A
group   of   women   with    borderline  serous  tumours  have   invasive
omental  or  peritoneal  implants.  In  a study  of  44  women  with  serous
borderline   tumours  between   3  and  9  years   later  four   women   with
invasive  implants died     despite  chemotherapy.
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DIAGNOSIS
Early   diagnosis   is   associated   with   a   better   outcome.  Hence
improvements   in   cure   rates   of   ovarian   cancer   are   likely   to   occur
when  prompt  diagnosis  and  appropriate  referral   is  performed.   The
symptoms   often  are  non  specific  and   may  mimic  other  conditions.
The usual  symptoms  are  bloating and abdominal  pain.  Change  in
bowel   habit,   backache,   weight   loss   and   menstrual   disorders  are  the
others.  An  average  general  practitioner  may  see  a  case  of  ovarian
cancer  once in  5  years.
Thus  the  non specific  nature  of  the  symptoms  may  lead  to  a
delay  of  upto  1  year in diagnosis. A  study  by  Goff et all  suggested
that  even  women   in   early  disease  experience   a   distinct   set   of
symptoms.  More   than   presence   of   symptoms   their   frequency   and
persistency  is  indicative  of  ovarian  cancer.
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INITIAL ASSESSMENT
It  is  estimated  that  5  to  10 %  of  women  in  their  life  time will
undergo  a  surgical  procedure  for  a  suspected ovarian  neoplasm. The
chance  of these  women  to  have  malignancy  is    13  to   21 % .  Since
the  majority  of   the  masses  are  benign    it   is   important   to  assess
preoperatively   whether   the  woman   is    at   high  risk   of    ovarian
malignancy.
For  a   woman  with  a  pelvic  mass  routine   assessment  should
include a full  history  and  examination,  vaginal  and  rectal  examination.
investigation should  include   an  ultrasound  of  abdomen  and  pelvis and
serum  CA 125   levels.  TVS  and  CA  125  remain  the  core  of  all  new
screening   strategies.   Ultrasound   and   CA  125   together   are   used   to
calculate   Risk of  Malignancy  Index.
RMI = U x  M  x  CA 125
U =   Ultrasound  score:
0 (if  none  present)
1 (if  only  one  feature present)
3 (if  2 – 5  features  present)
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Ultrasound  features :
? Multiple  cysts
? Solid areas
? Bilateral  lesions
? Ascites
? Metastases
M  =   1  if  premenopausal
M  =    3  if  postmenopausal
STAGING
Staging plays an important role in determining the  future
management   of   any   ovarian   carcinoma.   It  is  done   under   General
Anaesthesia.   Vertical   incision   is   suitable   for   staging.   The   incision
should   be   of   adequate   size   to   allow   exploration   of   the   entire
abdominal   cavity   and   removal   of   ovarian   massess   intact   where
possible. Staging comprises of ascitic or peritoneal fluid sampling
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systematic examination  of abdominal contents, peritoneal surfaces
retroperitoneal spaces, pelvic and para aortic lymph nodes and  infracolic
omentectomy .
PRIMARY  CYTOREDUCTION
     Primary cytoreduction  includes  cytology washings, TAH,  BSO ,
infracolic  omentectomy,      tumour  debulking,  surgical  staging   and
retroperitoneal node assessment.
OPTIMAL  DEBULKING
Cytoreduction  to  tumour   deposits  of  1  cm or  less is said to be
optimal debulking
This   approach  is  unique    to  ovarian  cancer . It is not done in
other   intra   abdominal   solid   tumours.   Better   survival   in   optimal
debulking than those with residual disease is evident by many
retrospective  studies  and  meta  analysis.  5.5 %  improvement  in  median
survival with every 10% improvement in the debulking rate was
demonstrated by meta analysis  off  7000 stage III/IV women with ovarian
cancer.
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ULTRA  RADICAL  SURGERY
There is evidence for improved outcome in operative  management
for   advanced   stage   disease.  But  it  is  achieved  only   when   all   the
macroscopic  disease is  completely  removed.  In  advanced stage disease
this  is   readily   achievable   in   22  -   25  %   of   cases  .  The   Gynaec
Oncology  Group, GOG  published  the  largest  series  to  date. They  used
six control  arms  of  different   prospective  randomized  trials.
Cisplatin   and   paclitaxel   chemotherapy  was  used.   There   were
1895  women  with  stage  III   ovarian  cancer.    23  %  were  cytoreduced
to no  visible  disease.  Progression  free  survival  was  33  months,  16.8
months,  14.,1  months  and  the  overall  survival  was  71.9  months,  42.4
months, 35.0  months  for  those  with  no  macroscopic  residual  disease,
0.1  to 1cm  residual  disease  and  greater  than  1  cm  residual  disease
respectively.
Similar   trends   are   shown  in   stage   IV  disease.   Winter   et   al
reported  on  366  patients    in  the   control  arms  of  4  GOG  studies.
Intravenous  cisplatin  and  paclitaxel were used.  The   maximal
cytoreduction  rate  was  8 %.    Those  patients  who  were  cytoreduced
to  no  residual  disease (progression  free  survival  20.1 months  and
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overall  survival  64.1  months) achieved maximum benefit.   Survival  for
patients   with   0.1  to   1  cm   residual   disease   had  no  difference   when
compared  with  1  to 5 cm  residual  disease.
Studies  claim  that  complete   cytoreductive  surgery  is  feasible.
Cyto reductive surgery  maximizes  survival  in  patients  with  advanced
disease.  Their  initial  surgical  cytoreduction rate  was  in  excess of  80
%. This  involves  an  ultra radical  approach.   It is a   more   aggressive
upper  abdominal  surgery  including  splenectomy.
It includes cholecystectomy, partial  pancreatectomy,   radical
stripping   of   the   peritoneum   and   multiple   bowel   resections.     post
operative  morbidity and  mortality were increased    operating  time was
longer.  Their  median  survival  however   was 75.8 months for  the  stage
III c disease .
LYMPHADENECTOMY
Overall survival advantage is not demonstrated by systematic
lymphadenectomy.   It  is  not   indicated   as   a  part  of   first   line
management.
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A     12 year  randomized  control trial   involving  13  centres   with
427  patients  and a long median  ( 68.4 months )  follow up examined  the
question  of  systematic  lymphadenectomy. There   was  a  modest
improvement  in  progression  free  survival  in  the  lymphadenectomy
arm. But it had  increased  morbidity which rules out its use.
EARLY   STAGE   DISEASE,  FIGO   STAGE   I  AND  II  A
EPITHELIAL  OVARIAN CANCER
Early  stage  ovarian  cancer  occurs  in  less  than   30%   of   women.
Stage I  cancer  is  relatively  more  frequent  in  women  under 40 years.
These women  may  wish  to  retain  fertility.  Standard  management
should   involve   TAH,  BSO    and   assessment   of   the   retroperitoneal
nodes.  In  younger  women   with  localised  unilateral    tumours ( FIGO
stage I )  it  is usual to  simply  remove   the  affected  ovary.  A  thorough
surgical  staging is essential.
If  the  other ovary is abnormal, wedge biopsy should be done When
the   ovarian   tumour   is     densely    adherent   to     other   pelvic  or
abdominal  structure, then  patient  should  be  upstaged.
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On  the  basis  of  the  available  evidence,  when  a  woman   wishes
to   retain   her   fertility  risk  of  recurrence  is  not  high  if   removal   of   a
single  abnormal   ovary   with   careful   examination    of   the   entire
abdominal  cavity  is done.  Washings  and  omental  biopsy  are  required
for  confirming  stage .
The  majority  of  ovarian  cysts  will be   found  to  be  benign.    Up
to  50 %  of  stage  I  ovarian  cancer  will  have  a  normal  CA 125  level.
There  is  no  evidence  to  justify  routine  lymphadenectomy.
STAGE  IV  DISEASE
There  is  survival  advantage  in a  small  number  of  women  (6%)
who  could  be  completely  debulked  as  per  the  GOG  study  on  stage
IV  ovarian  cancer. There  was  little  advantage  for  those  women  with
any  residual  disease.
 However   in   young   women   with   stage   IV   disease(  cytology
proven pleural effusion) surgical debulking should be considered, provided
there is   no  organ  dysfunction, disease is of  small  volume  disease  and
with good  performance  status   in  the  same  way   as  FIGO  stage   III
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disease.   The   other   alternative   will   be   NACT-S  if  a  response   was
obtained  with  chemotherapy.
SECOND  LOOK  LAPAROTOMY  OR  LAPAROSCOPY
After  the  completion  of  first line  chemotherapy  if a laparotomy
or laparoscopy is done  with the aim  of   assessing  disease  status  i.e.,
response  to  chemotherapy it is called as second look laparotomy or
laparoscopy.   There is  no  survival  benefit  for  second  look  laparotomy
as per available evidence.
In   the   routine  management   of   women   with   ovarian   cancer
second  look  laparotomy has  no  place.
INTERVAL  DEBULKING  SURGERY
If   initial   maximal   cytoreduction   was   not   performed    interval
debulking  should  be  considered  in  patients  who  are    responding  to
chemotherapy    or    showing   stable   disease.     It   should   be   done   as
soon  as  possible  once  necessary  cytoreduction  has  been  achieved
following   the   Goldie   Coldman    model.  Usually   3   cycles   of
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chemotherapy   are   given   followed   by   three   more   cycles   of
chemotherapy.
          425  women  were  enrolled    of in  EORTC trial   in   whom  319
were   subsequently   randomized.     If   they   had   not   been   optimally
debulked  the  women  are  eligible  for  the  study  (greater  than  1  cm
residual   tumour   deposit)  .  Those   who   responded   after   3   cycles   of
chemotherapy    were  randomized  to  interval  debulking  surgery or  no
further  surgery.  All  randomized  women  received  6  cycles  of  platinum
based  chemotherapy. They  demonstrated 6 months  median  survival
advantage.
A  subsequent  GOG  RCT of  424  women  showed  that  there  was
no  difference  in  median  survival.
The   current   standard   is   that  in   those   cases   where    maximal
cytoreduction  was  not  performed,  interval   debulking  should  be
considered.  This  is  in   patients     who   showed   response     to
chemotherapy   and   in   those    showing   stable   disease.   If   the  initial
surgical   debulking   was   performed  by  a   person   with   expertise   then
interval  debulking  surgery  is  not  recommended,  even  if   only
suboptimal  debulking  was  done.
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NEOADJUVANT  CHEMOTHERAPY  FOLLOWED  BY
SURGERY
Post  operative   mortality   is   3.7%  on   average    after   primary
cytoreductive   surgery.     It   is   more   frequent   for   elderly   women  in
whom  extensive  procedures  has  been  done.     The  strategy  of primary
chemo therapy  followed  by  surgery    in  potensially   resectable   cases
is  called  as Neoadjuvant  chemotherapy  ( NACT-S )
Comparison   of    NACT-S   with   the   standard   primary   surgery
followed  by  chemotherapy  using  platinum was  done  by the   EORTC
randomized  trial  55971 .   CHORUS  study  is  a  similar  study.  Interval
debulking  is no less  effective  than  up front  debulking  is  the  inference
of  initial  studies  of  55971 .
It  has   also   been   said   that   it   is     less   morbid   and    hence
NACT-S  should  be  more  widely  considered  than  previously.  Current
standard  is     For Those patients  who  are  not   fit   for   up frontsurgical
debulking  NACT-S  should  be  offered  .  It   should    also    be  offered   to
those  in  whom  optimal  debulking  is   unlikely.
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FIRST LINE  CHEMOTHERAPY  FOR  EPITHELIAL  OVARIAN
CANCER
EARLY  STAGE  DISEASE
Surgery  alone   is   adequate   for   the   FIGO   stage   IA,  IB  of
epithelial  ovarian  malignancy  in  which  tumour  was  well  differentiated
i.e   grade   1.   Also   the   histopathology   should   be   non   clear    cell.
Optimal  staging  should  have  been  done  for  the  patient.
The  role  of  adjuvant  chemotherapy  and  its  survival  advantage
has  been  confirmed  by    ICON 1 ( International Collaborative  Ovarian
Neoplasm )  and  also  by  the    ACTION ( Adjuvant  Chemo Therapy  in
Ovarian  Neoplasm)  ,  with  an  8 %   survival  advantage  at  6  years.
An    overall   hazard   ratio  of   0.72   is   give   by   the   Cochrane
review  in  favour  of  chemotherapy. Adjuvant  chemotherapy  is  required
in  poorly  differentiated  FIGO  Ia  and  Ib  and  histopathology  of  clear
cell  type.
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Dense  adhesions  if  present  they  are  significant  it  upstages  the
disease  and  adjuvant  chemotherapy  is  indicated.  Optimal  surgery  and
adjuvant  chemotherapy  is  required  in  all  stages  of  I C and  II A.
ADVANCED DISEASE
In stage  Ic- IIIc  of  epithelial  ovarian  cancer  the  recommended
standard   primary   chemotherapy   is   carboplatin  and  paclitaxel   for   6
cycles.  This  is    based    on two  trials  GOG III  and  OV  10.  NIH  and
NICE  advises  monotherapy   i.e.,  use  of  single  drug  either    cisplatin
or  carboplatin.
INTRAPERITONEAL  CHEMOTHERAPY
There   are   studies   which   compared    intravenous   chemotherapy
with  intraperitoneal    chemotherapy   and  they   have  shown improved
survival  in  patients  who   are  of   stage  III  ovarian  cancer  and  are
optimally  debulked.  There are  problems like   catheter related  morbidity.
There  are  also  problems  like   pain  and  bowel  obstruction.   Further
trials  are  awaited.
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NOVEL  CHEMOTHERAPEUTIC  AND  BIOLOGICAL  AGENTS
Hormonal   therapies,   antiangiogenic   drugs   and   growth   factor
inhibitors    are  the  novel  chemotherapeutic  agents where  research  is
going  on.  Their  main  advantage  is  that  they  have   minimal  adverse
effects.  Bevacizumab is   a  vascular  endothelial  growth  factor  inhibitor.
In  multiple  phase  II   studies it  has  demonstrated  significant  clinical
activity.
MATERIALS AND
METHODS
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MATERIALS AND METHODS
An  analytical   study of the patients who  underwent  treatment  for
epithelian  ovarian  carcinoma   in  Medical  Oncology  Department ,  IOG
Egmore from June 2012 to December  was conducted. Patients were
examined for demographic details, presenting symptoms, diagnostic
modalities  laboratory values, surgical procedures and  pathological
features, Data was  entered    in  to  a   standard proforma   and   analyzed.
Test of  significance  was done  with  pearson  Chi  square test.
The   study  included  a  population  of  89  patients  in  whom   a
diagnosis   of  epithelial    ovarian   malignancy   was  diagnosed   with
histopathology or  ascitic  fluid  analysis  confirmation of  epithelial
ovarian  malignancy .
INCLUSION CRITERIA:
1. Women who presented with clinical features , imaging features
and histopathological findings suggestive of epithelial ovarian
carcinoma registered in medical oncology department,   IOG
from  January  2012  to   June  2013  were  included  in  the
study.
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EXCLUSION CRITERIA:
1. Ovarian carcinomas other than epithelial ovarian carcinoma
2. Recurrent  epithelial ovarian carcinoma.
Ovarian  carcinomas  other  than epithelial carcinoma  were
excluded  from  the  study  because  epithelial  ovarian  malignancy  is a
separate  entity  in  malignant  ovarian  tumour  and  the  aim  of  the  study
is  to  analyse  the  epithelial  ovarian  carcinoma.
CA   125   the     tumour     of   epithelial   ovarian   malignancy   is
secreted   by   the   surface   epithelial   cells   of   the   ovary   from   where
epithelial  ovarian  malignancy  arises.  If  malignancies  other  than
ovarian   malignancy   is   included   in   the   study   then   it   will   interfere
with  the  comparison  of  CA 125  and  epithelial  ovarian  malignancy.
Patients   who  were   previously    dignosed   as   epithelial   ovarian
carcinoma underwent treatment for the same and  has come  with
recurrence    are  not    included  in  the  study.
Factors   like   age,   parity,    family   history,     presenting   features
were  analysed.    Use of  CA 125   as  a  diagnostic  modality   in epithelial
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ovarian  malignancy   was  analysed.  The  association   of  CA 125  with
the  stage  of   the  epithelial  ovarian  malignancy  was  analysed.  Test  of
significance used was pearson Chi square test. The association  of  CA 125
with   the  type  of  epithelial  ovarian  malignancy  was  tested  with  Chi
square  test.
STATISTICAL  ANALYSIS
Pearsons   Chi  square  test  was  used  for  analysis  of  data
OBSERVATIONAL
ANALYSIS
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TABLE 1 : DISTRIBUTION OF AGE INTERVAL
AGE  INTERVAL NO. OFPATIENTS PERCENTAGE
21 to 30 8 9.0
31 to 40 10 11.2
41 to 50 31 34.8
51 to 60 25 28.1
61 to 70 11 12.4
71 to 80 4 4.5
Total 89 100.0
* The study included 89 Patients.  Peak incidence occurred at 41 -50 years.
Mean age is 50 years.
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TABLE 2: DISTRIBUTION OF PLACE
PLACE FREQUENCY PERCENT
Chennai 45 50.6
Places around Chennai 32 36.0
Other place of TN 9 10.1
Other States 3 3.4
Total 89 100.0
* 86.6% of the patients are from places in and around Chennai. 10% are
from other places of Tamil Nadu. 3.4% are from other states.
51%
36%
10%
3%
Distribution of Place
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Places around Chennai
Other Place of TN
Other States
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TABLE 3: PARITY
Parity No. of patients Percent
Nullipara 10 11.2
Para 1 7 7.9
Para 2 30 33.7
Para 3 21 23.6
Para 4 12 13.5
Para 5 6 6.7
Para 6 2 2.2
Para 7 1 1.1
Total 89 100.0
* 11.2% are nulliparous . 88.8% are parous women
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TABLE 4: SURGERY/ ASCITIC FLUID ANALYSIS
Surgery Frequency Percent
Ovariotomy 6 6.7
TAH USO 2 2.2
TAH BSO 5 5.6
TAH BSO Omental Biopsy 17 19.1
TAH BSO Infra colic omentectomy 23 25.8
Ascitic Fluid Analysis 28 31.5
Open and Close Biopsy 4 4.5
TAH BSO   Omentectomy with LN 1 1.1
Subtotal hysterectomy  BSO Omental Biopsy 3 3.4
Total 89 100.0
[
* Omentectomy was done in  26.9% of cases .
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TABLE 5:  STAGE OF OVARIAN CANCER
Stage Frequency Percent
Borderline, IA, IB 10 11.2
IC, II 11 12.4
III 56 62.9
IV 12 13.5
Total 89 100.0
* 11.2% of the cases are borderline, 1A  & IB 76.4% Presented in
stage III & IV.
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TABLE 6:  CHEMOTHERAPY
Chemotherapy Frequency Percent
NACT 5 5.6
Adjuvant 33 37.1
Palliative 21 23.6
NACT -S 4 4.5
Not Given 26 29.2
Total 89 100.0
[
* NACT was given in 10.1% cases 37.1% were  given adjuvant
chemotherapy. 23.6% of patients were given palliative chemotherapy
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TABLE 7:  ONLY SURGERY
Only Surgery Frequency Percent
Only Surgery 9 10.1
Others 80 89.9
Total 89 100.0
* Only surgery was done in 10 % patients.
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Only Surgery
Only Surgery
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TABLE 8:  FAMILY HISTORY
Family_h/o Frequency Percent
Absent 88 98.9
Present 1 1.1
Total 89 100.0
* Most of the cases were sporadic. Family history  was  present in only
1.1%
99%
1%
Family History
Abstent
Present
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TABLE 9:  SERUM  CA 125
CA 125 Frequency Percent
> 35 U/mL 71 79.8
< 35 U/mL 18 20.2
Total 89 100.0
[
*  Serum CA 125 levels were raised in 79.8% of cases. In 20.2%
the levels were decreased
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TABLE 10:  HPE
HPE Frequency Percent
Serous 41 46.1
Mucinous 12 13.5
Endometriod 16 18.0
Clear Cell 3 3.4
Unclassified 17 19.1
Total 89 100.0
* 46.1 % of cases were serous. 18% were  endometrioid. 13.5%
cases were mucinous. 3.4 % were clear cell carcinoma.
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HPE
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TABLE 11:  DISTENSION
DISTENSION Frequency Percent
Present 56 62.9
Absent 33 37.1
Total 89 100.0
* 62.9 %  patients presented with distension.
63%
37%
Distension
Present
Absent
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TABLE 12:  PAIN
PAIN Frequency Percent
Present 61 68.5
Absent 28 31.5
Total 89 100.0
* 68.5 % patients presented with pain in abdomen or pelvis.
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TABLE 13:  MASS
MASS Frequency Percent
Absent 7 7.9
Total 89 100.0
* 7.9%  of patients  presented with mass abdomen.
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TABLE 14:  DYSPEPSIA
DYSPEPSIA Frequency
Dyspepsia Present 14
Absent 75
Total 89
* 16% patients presented with dyspepsia.
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TABLE 15:  LOSS OF APPETITE
LOA Frequency Percent
Loss of Appetite 33 37.1
Absent 56 62.9
Total 89 100.0
* 37.1 %  of patients presented with loss of appetite.
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TABLE 16:  LOSS OF WEIGHT
LOW Frequency Percent
Loss of Weight 20 22.5
Absent 69 77.5
Total 89 100.0
* 22% of patients  presented with loss of weight.
22%
78%
LOSS OF WEIGHT
Loss of Weight Absent
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TABLE 17:  ASYMPTOMATIC
ASYMPTOMATIC Frequency Percent
Asymptomatic 1 1.1
Symptomatic 88 98.9
Total 89 100.0
* Disease was asymptomatic in 1.1%
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TABLE 18:  PRESSURE SYMPTOMS
PRESSURE
SYMPTOMS Frequency Percent
Pressure Symptoms 10 11.2
Absent 79 88.8
Total 89 100.0
* 11.2 % of patients presented with pressure symptoms like
increasedfrequency of  micturition  and  breathlessness.
11%
89%
pressure Symptoms
Pressure Symptoms Absent
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TABLE 19:  MENSTRUAL SYMPTOMS
MENSTRUAL
SYMPTOMS
Frequency Percent
Present 6 6.7
Absent 83 93.3
Total 89 100.0
* 6.7 % presented with  menstual symptoms.
7%
93%
Menstrual Symptoms
Present
Absent
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Stage  and Chemotherapy
Chemotherapy Total
NACT Adjuvant Palliative NACT
–S
Not given
Stage
Borderline,
I A & IB
0 1 0 0 9 10
IC, II 0 7 0 0 4 11
III 4 24 15 3 10 56
IV 1 1 6 1 3 12
Total 5 33 21 4 26 89
70% of women  with  stage  IC  and higher  were given  chemotherapy.
50% of chemotherapy  was adjuvant chemotherapy.
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TEST  OF  ASSOCIATION – CHI  SQUARE TEST
Stage  and Age comparision
Age in  Years
age interval
Total21-30 31-40 41-50 51-60 61-70 71-80
 Borderline,
I A & IB
3 1 3 1 2 0 10
IC, II 2 1 4 2 1 1 11
III 3 6 19 19 6 3 56
IV 0 2 5 3 2 0 12
Total 8 10 31 25 11 4 89
In  women  below  40  years   40% of the  tumours were borderline, stage I
A and stage I B.   60% were of  I C and above. In women above  40  years
82 % were I C and above.
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TEST  OF  ASSOCIATION – CHI  SQUARE TEST
Serum CA 125   level were raised in 40% of  borderline, stage IA and IB.
Serum CA 125 level  were  raised  in 84 % of late stage disease.
There is  significant  association  between  CA 125  and  stage  of  the
disease.  P   value  0.003
Stage  and  CA125  association
CA_125
Total
>35U/mL <35U/mL
Stage Borderline,Ia,
Ib
4 6 10
IC , II 8 3 11
III 47 9 56
IV 12 0 12
Total 71 18 89
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CA 125  and Histopathology
HPE Total
serous mucinous
Endo
metroid
Clear
cell
Un
classified
CA
125
> 35 35 2 14 3 17 71
<  35 6 10 2 0 0 18
Total 41 12 16 3 17 89
Serum CA 125 levels were normal in  84 % of mucinous carcinoma.
Serum  CA 125  levels  were raised in  86 % of epithelial  malignancy
other than  mucinous carcinoma.
 There is significant   (<0.05)  association  between  CA 125  and
histopathology of epithelial ovarian  carcinoma. P=0.000
DISCUSSION
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DISCUSSION
? Our Study involved 89 patients with epithelial ovarian cancer. The
peak incidence of epithelial ovarian cancer in our study was between
41 to 50 years. Mean age is 50 years.
? Minimum age at which epithelial ovarian carcinoma occurred in our
study was at 22 years.
? Maximum age  at which epithelial ovarian carcinoma occurred in
our study was at 80 years.
? 86.6% of the places were from in and around Chennai. 10 % are
from other places of Tamilnadu. 3.4 % are from other states.
? Most of the cases were sporadic
? Incidence of ovarian malignancy in nulliparous women in our study
was 11.2% where as 88.8% occurred in multiparous women. But in
published studies the incidence is more in nulliparous women.
? 62.9% of Patients presented with distention.  68.5 % presented with
pain in abdomen or pelvis. 7.9% presented with mass abdomen.
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37.1% complained of loss of appetite. 16% had dyspepsia.  Loss of
weight was present in 22.5%.  1.1% was asymptomatic . 11% had
pressure symptoms like increased frequency of micturition or
breathlessness . 6.7 % presented with menstrual symptoms.
? Published series  in epithelial ovarian malignancy also says that the
ussaual symptom are  vague abdominal symptoms and  and pressure
symptoms involving bladder.
? 11.2% of cases were borderline IA and 1B. grade 1. 88.8%  were of
IC and higher stage which need adjuvant chemotherapy . This is in
accordance with the other studies in epithelial ovarian
malignancy.The malignancy usually presents at later stages.
? Serum CA 125 levels were normal in 20.2%  of cases.  In 79.8% CA
125  level  was  raised.   CA  125  level  were  normal  in  84%  of
mucinous  carcinoma.   In  86%  of  other  types   CA  125  level  were
raised. There is significant  association between  CA 125 and
histopathology of epithelial  ovarian  carcinoma. P=0.000
? Serum  CA  125  level  was  raised  in   only  40%  of  patients  with
borderline, stage IA and I B .  Serum CA 125 level  was  raised in 84
72
%  of  patients  with  stage   I  C  and  above.There  was  significant
association   between    serum  125  level  and   stage  of  the  disease.
P=0.003
? Serous carcinoma occurred in 46.1% cases.
? Endometrioid  carcinoma occurred in 18.0% cases.
? Mucinous carcinoma in 13.5% cases.  3.4 % were clear cell
carcinoma.
? Only  surgery  was   done  in  10  %  cases.  They   were  early  stage
disease.  Omentectomy was done in 26.9% of cases.  Subtotal
hysterectomy was done in 3.4% of cases.
?  NACT was given in 10.1% cases 37.1% were  given adjuvant
chemotherapy. 23.6% of patients were given palliative
chemotherapy.  6  cases  of  NACT  was  followed  up.   All   showed
reduction in size of the tumour. Further larger studies are needed  to
commit on this
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? 70%  of  women   with   stage   IC   and  higher   were  given
chemotherapy.  Out  of  the  total  number  of  chemotherapy,   50%  of
chemotherapy  was adjuvant chemotherapy.
SUMMARY
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SUMMARY
? 89 women with epithelial ovarian  carcinoma were selected for the
study.
? Recurrent  cases of epithelial ovarian malignancy were excluded.
? 62.9% of patients were between  41 and 60 years.  Maximum
number  of  patients  were  between 41 and 50 years. Mean age of
occurrence of  epithelial ovarian  malignancy in our study was 50
years.
? Minimum age at which epithelial ovarian carcinoma occurred in our
study was at 22 years.
? Presenting complaints of the patients were collected
? Serum CA 125 level at presentation was collected
? Type of carcinoma was evaluated  by either  histopathological
examination or ascitic fluid analysis
? Type of surgery and chemotherapy given was analysed.
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? Association between   serum CA 125 and histopathology  was
tested by pearson Chi square test. There  was significant association
between CA 125 and histopathology. In  mucinous  carcinoma  CA
125 levels were low
? Association between   serum CA 125 and  stage  of the disease was
tested by pearson Chi square test. There was significant association
between  CA 125 and stage of the disease.
CONCLUSION
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CONCLUSION
Mean age of occurrence of epithelial ovarian carcinoma in our study
was 50 years.
Epithelial ovarian malignancy is more common in our population in
multiparous women.
Epithelial ovarian malignancy is sporadic in most of the cases.
Most of the cases of epithelial ovarian malignancy present with
distension and vague gastrointestinal and pressure symptoms like increased
frequency of  micturition.
Serum CA 125  is a useful diagnostic modality in women presenting
with these symptom.
Adjuvant chemotherapy is the most common mode of
chemotherapy.
ANNEXURE
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PROFORMA
PROFORMA
Introduction
• Name of patient wcc no:
• Age of patient
• occupation
Presenting Complaint
History of Presenting Complaint Duration
• Abdominal distension
• Feeling of a lump in the abdomen
• Abdominal pain
• Dyspepsia
• Bloating
• Early satiety
• Abdominal discomfort
• Loss of appetite
• Loss of weight
• Urinary frequency
• Urinary retention
• Constipation
• Abnormal uterine bleeding
Pelvic pain
• If pain is involved ascertain site, radiation (if any) and character
• Onset
• Periodicity
• Duration
• Recurrence?
• Aggravating & relieving factors
• Severity
• Previous sexually transmitted infections
• Dyspareunia - deep or superficial
Change in bladder habits
• Pain during urination
• urinary frequency
• Urinary retention
• Blood in the urine
Change in bowel habit
• Constipation.
• Difficulty in bowel movement
• Blood in the stool
• Weight loss
• Loss of appetite Menstrual History
• Age at menarche and menopause
• 1st day of last menstrual period
• Length of bleeding (days)
• Frequency
• Regularity
• Bleeding between periods
• Bleeding after intercourse
• post menopausal bleeding
Past Gynecological History
• Gynecological diagnoses
• Gynecological surgery
• Date & result of cervical smears
• Contraception Past Obstetric History
• Gravidity and Parity
• Normal Delivery/caesarean
• Any terminations
• Any miscarriages
• Any ectopic pregnancies
Drug History
• Hormone replacement therapy
• Use ovulation induction
• Oral contraceptive pills
• Any known drug allergies .
Past Medical History
• Past operations
• Diabetes
• Hypertension
• Other medical conditions
• Current or past illnesses
• Hospital admissions
• Past surgeries
Family History
• Family history of hypertension, diabetes
• Family history of breast cancer / ovarian cancer /endometrial
cancer/ colon cancer/ other gynaecological cancers
Personal History
• estrogen replacement therapy
• smoking
• alcohol
Pap Smear History
• When last smear
• Always normal?
• Any previous problems
• Ever had a colposcopy?
General Examination:
• Ht
• Wt
• BSA
• BMI
• Pulse
• Blood Pressure
• Respiratory Rate
• Temperature
• Anemia
• Cyanosis
• Jaundice
Systemic examination:
CVS: RS:
CNS:
ABD:
PER VAGINAL EXAMINATION:
Investigations
• Complete blood count:   N/ABN
• Blood chemistry tests
• LFT: N/ABN
• Pap smear
• Endometrial biopsy in case of AUB
• Endoscopy
• Cystoscopy
• Colonoscopy
• Chest x-ray
• Ultrasound
• Computed tomography (CT) scan/ MRI
• Tumour markers
DIAGNOSIS:
TREATMENT
Surgery
? Staging laparotomy Done/Not Done
? Total abdominal hysterectomy, bilateral salpingo oopherectomy,
infracolic omentectomy, ascitic fluidcytology, peritoneal nodule
sampling, lymphnode sampling
? Adjuvant chemotherapy
? Neoadjuvant chemotherapy
Histopatologic examination:
? Serous
? Mucinous
? Endometroid
? Clear cell
? Brennar
? Mixed epithelial
? Undifferentiated
? Unclassifie
? Grade of carcinoma: I II II
? Unilateral/Bilateral
Follow up:
? Complaints
? Systemic examination
? Per Abd examination
? Per Vaginal examination
? CBC
? CA 125
? Ultrasound

CONSENT FORMS


ABBREVATIONS
KEY TO THE MASTER CHART.
P – PARA
TAH – TOYAL ABDOMINAL HYSTERECTOMY
SAH – SUBTOTAL ABDOMINAL  HYSTERECTOMY
BSO – BILATERAL SALPINGO OOPHORECTOMY
ICO  -  INFRACOLIC OMENTECTOMY
TO – TOTAL OMENTECTOMY
OB – OMENTAL BIOPSY
LN – LYMPH NODE SAMPLING
DIB – DIFFICULTY IN BREATHING
DIM -  DIFFICULTY IN MICTURITION
NACT – NEOADJUVANT CHEMOTHERAPY
NACT-ADJ -   NACT  - SURGERY – ADJUVANT
S+O – ONLY SURGERY
ABBREVIATIONS
TVS – TRANS VAGINAL SONOGRAPHY
CA 125 – CANCER ANTIGEN 125
TAH – TOTAL ABDOMINAL HYSTERECTOMY
BSO – BILATEREL SALPINGO OOPHORECTOMY
ICON – INTERNATIONAL COLLABORATION ON OVARIAN
NEOPLASM
ACTION – ADJUVANT CHEMOTHERAPY  IN OVARIAN
NEOPLASM
CHORUS – CHEMOTHERAPY OR UPFRONT SURGERY
GOG – GYNAEC ONCOLOGY GROUP
ROCA – RISK OF OVARIAN CANCER ALGORITHM
RMI – RISK OF MALIGNANCY INDEX
NACT -  NEOADJUVANT CHEMO THERAPY
NACT –S-   NEOADJUVANT CHEMOTHERAPY

 MASTER CHART
date WCC:NO
NAME
AGE PLACE PARITY FAMILY HIS CA-125 PRESENTING SYMPTOMS DIAGOSIS
SURGERY/CYTOLOG
Y/FNAC
STAGE, GRADE CHEMOTHERAPY
SURGERY+
OBSERVA
TION
05.01.12 004/12 Nanjammal 50 Krishnagiri P5L5 yes 11136 distension,vomiting,abdominal pain,LOW,LOA,diB endometrioid carcinoma TAH BSO ICO IIIC, 2 NACT O
09.01.12 006/12 Lakshmi 40 Dharmapuri P1L1 NO 216 distension,vomiting,abdominal pain,LOW,LOA,diB serous epithelial carcinoma TAH BSO OB  IV,3 NACT+adjuvant O
18.01.12 013/12 Balamani 55 Salem P2L2 NO 17 LOA,LOW, dyspepsia mucinous carcinoma ovariotomy IIIc,3 adjuvantCT O
08.02.12 026/12 Panchalai 49 Chennai P4L4 NO 17 distension serous epithelial carcinoma TAH BSO ICO IIIc,3 NACT+adjuvant O
08.02.12 027/12 Manjula 39 Vellore P3L3 NO 2473 distension,vomiting,abdominal pain,LOW,LOA,diB serous epithelial carcinoma Ascitic fluid analysis IIIc,3 NACT O
09.02.12 028/12 Anjali 27 Chennai P2L2 NO 131 distension,pain serous epithelial carcinoma TAH BSO ICO IIa,1 adjuvantCT O
23.03.12 037/12 Mahadevi 35 Chennai P2L2 NO 207 endometrioid adenocarcinomaTAH BSO OB IIIc,1 adjuvantCT O
05.03.12 045/12 Navaneetham 48 Ambur P2L2 NO 8334 distension,dyspepsia,diB,Duo serous epithelial carcinoma TAH BSO OB IIIc,3 adjuvantCT O
05.03.12 046/12 Vijayalakshmi 45 Chennai P3L2 NO 48 fever serous epithelial carcinoma OB Ivb,3 adjuvantCT O
06.03.12 049/12 Ranjitham 65 Chennai P4L3 NO 2528 distension,pain,LOA serous epithelial carcinoma staging/biopsy IIIc,3 NACT O
15.03.12 058/12 Chandra 50 Chennai P2L2 NO 6 pain mucinous adenocarcinoma BSO(post VH) Ic,1 NG S+O
03.04.12 075/12 Kalpana 26 Chennai P2L2 NO 32 pain serous epithelial carcinoma ovariotomy Ia,1 NG S+O
03.04.12 076/12 Prema 58 Chennai P4L3 NO 126 pain,distension,LOA serous epithelial carcinoma TAH BSO OB IIIc,2 adjuvantCT O
19.04.12 083/12 Rani 80 Chennai P2L2 NO 878 pain,vomiting,LOA,LOW serous epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
12.05.12 097/12 Panchalai 70 Chennai P6L4 NO 6.5 pain,distension,mass mucinous adenocarcinoma TAH BSO Ia,1 NG S+O
15.05.12 102/12 Indra 47 Chennai nullipara NO 11 mass abdomen serous epithelial carcinoma TAH BSO IIIc,2 adjuvantCT O
19.05.12 108/12 Gowsiya 28 Chennai nullipara NO 14 pain mucinous adenocarcinoma ovariotomy IIIc,3 NG O
19.05.12 110/12 Shanthi 46 Kanchipuram P3L3 NO 19 pain,distension,LOA,LOW serous epithelial carcinoma TAH BSO OB Ic,1 adjuvantCT O
21.05.12 115/12 Mumtaj 50 Chennai P5L5 NO 148 pain,distension serous epithelial carcinoma TAH BSO ICO IIIc,3 adjuvantCT O
05.06.12 136/12 Indirani 67 Chennai P3L3 NO 240 pain,distension,LOA,LOW serous epithelial carcinoma TAH BSO OB IIIc,3 adjuvantCT O
12.06.12 144/12 Fathimabee 65 Chennai P3L2 NO 890 distension,pain,LOA,LOW serous epithelial carcinoma staging/biopsy IIIc,3 palliativeCT O
15.06.12 158/12 Nirmala 50 Chennai P2L2 NO 8890 distension,pain,LOA,LOW serous epithelial carcinoma TAH BSO ICO IIIc,3 NACT+adjuvant O
26.06.12 174/12 Baby 52 Chennai P2L2 NO 45 distension,pain, mucinous adenocarcinoma Ascitic fluid analysis IIIc,3 NACT O
28.06.12 176/12 Bhavani 46 Chennai P2L2 NO 128 menorrhagia,dysmenorrhoea clear cell carcinoma TAH LSO Ic,2 adjuvantCT O
03.07.12 183/12 Kuzhandaiammal 60 Salem P4L3 NO 800 pain,LOA epithelial carcinoma Ascitic fluid analysis Iva,3 NACT O
05.07.12 184/12 Fathimagani 58 Chennai P3L3 NO 600 pain,spotting,LOA endometrioid adenocarcinomaTAH BSO OB Ic,2 adjuvantCT O
10.07.12 188/12 Deivanai 31 Vellore P2L2 NO 750 mass abdomen, pain endometrioid adenocarcinomaTAH BSO Ic,1 adjuvantCT O
16.07.12 192/12 Padmavathy 57 Chennai P2L2 NO 258 pain,distension,LOA,LOW serous epithelial carcinoma Ascitic fluid analysis Iva,3 palliativeCT O
16.07.12 193/12 Kanagam 56 Chennai P2L2 NO 670 dyspepsia,LOA endometrioid adenocarcinomaTAH BSO OB IIIc,3 adjuVantCT O
01.08.12 198/12 Patchaiammal 52 Avadi P2L2 NO 600 pain,distension serous epithelial carcinoma TAH BSO OB IIIc,3 adjuvantCT O
08.08.12 206/12 Nasreen 48 Chennai P2L2 NO 1549 distension,pain serous epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
17.08.12 219/12 Bharathi 35 Chennai nullipara NO 650 distension,pain,diB,LOA serous epithelial carcinoma TAH BSO ICO IIIc,2 adjuvantCT O
22.08.12 223/12 Santhosammal 70 Nellore P4L3 NO 92 dyspepsia,LOA serous epithelial carcinoma TAH BSO OB Ia,1 NG S+O
27.08.12 228/12 Rajeswari 55 Avadi P5L5 NO 1331 pain,distension,LOA epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
04.09.12 242/12 Ganga 52 Chennai P7L3 NO 12000 pain,distension,LOA,LOW serous epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
04.09.12 243/12 Mallika 50 Kanchipuram P5L4 NO 18 pain,distension mucinous adenocarcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
17.09.12 260/12 Seivi 42 Seergali P3L3 NO 3814 pain serous epithelial carcinoma TAH BSO OB IIIc,2 adjuvantCT O
21.09.12 261/12 Kuppu 30 Vellore P3L3 NO 1120 pain,difficulty in breathing serous epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
25.09.12 267/12 Pushpa 54 Chennai nullipara NO 6 Dyspepsia,LOA endometrioid adenocarcinomaTAH BSO OB IIIa,2 adjuvantCT O
26.09.12 270/12 Suseela 50 Thiruvannamalai P2L1 NO 503 mass,LOA,LOW epithelial carcinoma Ascitic fluid analysis Ivb,3 NG O
27.09.12 272/12 Selvi 54 Vellore P3L3 NO 487 white discharge pv endometrioid adenocarcinomaTAH LSO IIIc,3 adjuvantCT O
01.10.12 275/12 Nagapoosanam 45 Chennai P2L2 NO 88 pain,LOA,LOW epithelial carcinoma Ascitic fluid analysis IV,3 palliativeCT O
date WCC:NO
NAME
AGE PLACE PARITY FAMILY HIS CA-125 PRESENTING SYMPTOMS DIAGOSIS
SURGERY/CYTOLOG
Y/FNAC
STAGE, GRADE CHEMOTHERAPY
SURGERY+
OBSERVA
TION
01.10.12 276/12 Gunasundari 55 Thiruvannamalai P4L2 NO 6629 pain,distension,diM, dyspepsia serous epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
03.10.12 278/12 Rajeshwari 50 Thiruvannamalai P2L2 NO 4261 pain,distension,dyspepsia,LOA,LOW serous epithelial carcinoma staging/biopsy IIIc,3 palliativeCT O
06.10.12 288/12 Nithya 22 Chennai nullipara NO 18 pain borderlinemucinous adenocarcinomaovariotomy Ia NG S+O
08.10.12 289/12 Sagayamary 40 Chennai nullipara NO 1032 mass,LOA,LOW clear cell carcinoma TAH BSO Ic,2 NG O
09.10.12 296/12 Ammaniammal 65 Villupuram P3L3 NO 1246 pain,distension,LOA,LOW,constipation epithelial FNAC Ascitic fluid analysis Ivb,3 palliativeCT O
09.10.12 298/12 Kuppu 30 Vellore P3L3 NO 1120 pain,distension epithelial carcinoma Ascitic fluid analysis IIIc,3 NG O
09.10.12 299/12 Sarasu 38 Thiruvannamalai nullipara NO 416 distension,LOA,LOW serous epithelial carcinoma TAH BSO OB IIIc,3 adjuvantCT O
17.10.12 312/12 Mariammal 37 Coimbatore P3L3 NO 401 distension,difficulty in breathing epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
26.10.12 325/12 Amirtham 60 Chennai P2L1 NO 39 pain serous epithelial carcinoma TAH BSO ICO IIIc,3 adjuvantCT O
05.11.12 333/12 Padmavathy 42 Thiruvannamalai P2L2 NO 358 pain,menorrhagia endometrioid adenocarcinomaTAH BSO ICO Ia,1 NG S+O
05.11.12 334/12 Unnamalai 62 Vellore P3L2 NO 34 bleeding pv,white discharge pv serous epithelial carcinoma TAH BSO OB II a,3 adjuvantCT O
10.11.12 340/12 Amirthammal 71 Chennai P2L1 NO 386 pain,distension,LOA,LOW serous epithelial carcinoma Ascitic fluid analysis IIIc,3 NG O
14.11.12 344/12 Govindammal 55 Chittur P4L3 NO 269 pain,distension,nausea,dyspepsia epithelial carcinoma Ascitic fluid analysis Ivb,3 palliativeCT O
19.11.12 348/12 Peryayee 50 VillupuramP5L5 NO 970 pain,LOA,LOW epithelial carcinoma Ascitic fluid analysis Ivb,3 NG O
19.11.12 350/12 Jothi 51 Chennai nullipara NO 62 difficulty in breathing epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
22.11.12 353/12 Parvathy 57 kanchipuram P4L4 NO 600 dyspepsia,LOA serous epithelial carcinoma TAH BSO TO LN IIIc,2 NACT+adjuvant O
22.11.12 358/12 Madhaviammal 78 Kodungaiyur P5L3 NO 318 pain,difficulty in micturition serous epithelial carcinoma TAH BSO ICO II c,3 NG O
24.11.12 362/12 Manimegalai 37 Periyakanchipuram P1L1 NO 78 pain,nausea,vomiting endometrioid adenocarcinomaLSO I a,1 NG O
25.11.12 363/12 Dhanabhagiyam 45 Periyakanchipuram P2L0 NO 4250 distension,LOA,LOW epithelial carcinoma Ascitic fluid analysis III c,3 palliativeCT O
27.11.12 368/12 Premavathy 50 Chennai P3L3 NO 53 pain Serous epithelial carcinoma TAH BSO ICO IIIc,3 adjuvantCT O
10.12.12 389/12 nagarathinam 65 Chennai P2L2 NO 1178 dyspepsia serous epithelial carcinoma TAH BSO ICO IIIb,1 adjuvantCT O
15.12.12 398/12 Prema 38 Chennai P2L2 NO distension,pain mucinous adenocarcinoma ovariotomy Ia,1 adjuvantCT S+O
28.12.12 411/12 Suriyakumari 45 Chennai P4L4 NO 304 pain,distension,vomiting,PE B/l endometrioid adenocarcinomaTAH BSO ICO IIIc,3 NG O
08.01.13 009/13 Niraimathi 50 Kanchipuram nullipara NO 33 pain B/l endometrioid adenocarcinomaSAH BSO OB IIIc,2 adjuvantCT O
09.01.13 010/13 Jayanthi 45 Chennai P3L3 NO 163 pain,distension endometrioid adenocarcinomaTAH BSO ICO Ia,3 AdjuvantCT S+O
21.01.13 026/13 Premavathy 52 Chennai nullipara NO 4333 distension B/l endometrioid adenocarcinoma,adrenal adenomaTAH BSO ICO ADRE IIIc,3 adjuvantCT O
23.01.13 031/13 Lakshmi 35 Chennai P4 L4 NO 619 pain,distension,BSWD malignant surface epithelial tumour and squamous cell carcinoma cervixAscitic fluid analysis Ivb,3 NG O
25.01.13 036/13 Ranjitham 65 Kandigai P4 L4 NO 3872 pain,distension,LOA,LOW epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
28.01.13 037/13 Palaniyammal 55 Dharmapuri P2L2 NO 396 pain,distension B/l serousepithelial cystadeno carcinomaTAH BSO ICO IIIc,2 adjuvantCT O
04.02.13 046/13 Ayeshabee 75 Kanchipuram P2L0 NO 2361 distension,pain,vomiting B/l serous epithelial cystadeno carcinomaSAH BSO OB IIIc,3 NG O
08.02.13 053/12 saraswathy 59 Chennai P2L2 NO 17 distension,pain mucinous cysadenocarcinomaTAH BSO ICO Ib,1 NG O
11.02.13 055/13 Krishnammal 55 Gumidipoondi P2L2 NO 9819 distension,pain malignant surface epithelial tumourAscitic fluid analysis IIIc,3 NG O
15.02.13 058/13 Chokkammal 42 Thenkalaikottai p3l3 NO 1972 distension,pain malignant surface epithelial tumourAscitic fluid analysis Ivb,3 palliativeCT O
13.02.13 062/13 Syrajunisha 55 Vellore P6L6 NO 55 distension,pain malignant surface epithelial tumourAscitic fluid analysis IIIc,3 palliativeCT O
18.02.13 068/13 Rani 45 Ooty P3L3 NO 53 pain,vomiting,spotting B/l endometrioid adenocarcinomaTAH BSO ICO IIIc,3 NG O
10.04.12 133/13 Motchalangaram 45 Chennai P2L2 NO 76 pain endometrioid adenocarcinomaTAH BSO ICO IIIa,2 adjuvantCT O
10.04.12 135/13 Muniammal 50 Thiruvannamalai P3L3 NO 4896 pain,distension mucinous cysadenocarcinomaTAH BSO ICO IIIc,2 NG O
13.04.12 138/13 Sagunthala 65 Thiruvannamalai P1L1 NO 23 distension mucinous cysadenocarcinomaSAH BSO OB IIIc,3 adjuvantCT O
02.05.13 159/13 Valliammal 56 Chennai P2L2 NO 97 pain,LOW serous epithelial carcinoma TAH BSO IIIc,3 NG O
07.05.13 166/13 Stellamary 27 Chennai nullipara NO 134 pain.distention endometrioid adenocarcinomaTAH BSO ICO Ic,1 NG O
10.05.13 173/13 Komala 43 Chennai P3L3 NO 10 distension,dyspepsia,pain borderline mucinous tumour TAH BSO OMENTAL BIOPSY Ia NG S+O
18.05.13 183/13 kanthammal 50 Vellore P3L3 NO 167 distension,pain,leg swelling serous epithelial carcinoma Ascitic fluid analysis IIIc,3 palliativeCT O
29.05.13 197/13 Saratha 45 Vellore P3L3 NO 9 distension,dyspepsia B/l serous epithelial cystadeno carcinomaTAH BSO ICO IIIc,3 adjuvantCT O
03.06.13 203/13 Saraswathy 65 Avadi P1L1 NO 13064 pain,dyspepsia malignace epithelial tumourant surfA citic fluid analysis Ivb,3 palliativeCT O
04.06.13 205/13 Minnalkodi 28 Chennai nullipara NO 16 distension,pain borderline mucinous tumour TAH BSO ICO Ia NG S+O
05.06.13 208/13 Rajeswari 55 Cuddalore P2L2 NO 389 pain clea rcell carcinoma TAH BSO ICO IIIc,3 NG O
24.06.13 252/13 lavanya 54 Chennai P4 L4 NO 1359 distension serous epithelial carcinoma TAH BSO ICO II c,3 adjuvantCT O
